Michael Gerard Campbell - 27 Nov 2023 Form 4 Insider Report for Comera Life Sciences Holdings, Inc.

Role: EVP & CFO
Signature: /s/ Ryan M. Rourke Reed, Attorney-in-Fact
Issuer symbol: CMRA on OTC
Transactions as of: 27 Nov 2023
Net transactions value: +$708
Form type: 4
Filing time: 28 Nov 2023, 16:25:36 UTC
Previous filing: 28 Sep 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CMRA	Common Stock	Purchase	$708	+10,000	+40%	$0.0708	35,000	27 Nov 2023	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.0675 to $0.07125, inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

Content

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.0675 to $0.07125, inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.